BioSpace News Archive

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced an update on its CD73 inhibitor program.

Johnson & Johnson announced new data reinforcing the strong and long-lasting protection of its COVID-19 vaccine.

BioCryst Pharmaceuticals, Inc. announced that the company will present at the 2021 Cantor Virtual Healthcare Conference on Tuesday, September 28, 2021 at 2:00 p.m. ET.

Lyra Therapeutics, Inc. announced that the positive results of the Company’s Phase 2 LANTERN study of LYR-210 were published online in the peer-review journal, International Forum of Allergy & Rhinology.

Willow Biosciences Inc. is pleased to provide the following operational and corporate updates.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced it will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 8:40 a.m. ET.

NanOlogy LLC, a clinical-stage interventional oncology drug company, announced that initial results from a Phase 1/2 clinical trial of intramural/intravesical NanoDoce® suspension in high-risk nonmuscle invasive bladder cancer were presented by Max Kates, MD at the American Urological Association annual meeting via virtual platform on September 12, 2021.

Vildagliptin is an antihyperglycemic medication that inhibits the dipeptidyl peptidase-4 enzyme selectively.

External counterpulsation is a non-invasive and medically proven treatment recommended for patients with angina or congestive heart failure condition.

Fact.MR – A Market Research and Competitive Intelligence Provider: As per the latest Fact.MR analysis, the global hepatitis rapid testing market is forecast to register high growth between 2021 and 2031.